Table 1.
Baseline characteristics of patients with serum creatinine elevation and proteinuria while receiving benmelstobart plus anlotinib
| Characteristics | Serum creatinine elevation (N = 100) | Proteinuria (N = 169) |
|---|---|---|
| Age (years), < 65 | 65 (65.00) | 103 (60.95) |
| Male sex | 78 (78.00) | 135 (79.88) |
| BMI, < 25 | 53 (53.00) | 101 (59.76) |
| Hypertension | 47 (47.00) | 79 (46.75) |
| Diabetes | 20 (20.00) | 29 (17.16) |
| ECOG performance status | ||
| 0 | 25 (25.00) | 42 (24.85) |
| 1 | 75 (75.00) | 127 (75.15) |
| KPS | ||
| 90-100 | 75 (75.00) | 36 (21.30) |
| 70-80 | 25 (25.00) | 133 (78.70) |
| IMDC prognostic risk | ||
| Favourable | 18 (18.00) | 26 (15.38) |
| Intermediate | 73 (73.00) | 120 (71.01) |
| Poor | 9 (9.00) | 23 (13.61) |
| History of nephrectomy | 79 (79.00) | 109 (64.50) |
| eGFR, < 90 mL/min/1.73 m² | 86 (86.00) | 127 (75.15) |
Data are n (%). Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky performance status; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; eGFR, estimated glomerular filtration rate